Compare prices and buy KLOW Blend from 45 research peptide vendors - also called suppliers or sources. Updated daily.
GHK-Cu + TB-500 + BPC-157 + KPV
A four-peptide research blend that adds KPV, a tripeptide from the C-terminus of alpha-melanocyte-stimulating hormone, to the GLOW combination of GHK-Cu, BPC-157 and TB-500. The four act through unrelated mechanisms studied in cell-culture and preclinical models, and the combination has not been evaluated in a controlled human trial. Vendors load several times more GHK-Cu than any other component, so most of the vial's mass is the copper peptide. For research purposes only.
For research purposes only. Not medical advice.
KLOW is a fixed combination of four research peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. As a mixture, it carries no CAS number of its own. "KLOW" is vendor branding, GLOW with its G swapped for the K of KPV.
An 80 mg vial holds 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV. That is GLOW's 50/10/10 formula with a 10 mg KPV load added, and where a vendor appends the load to the name, KLOW-80 is a strength rather than a separate formula. The family is a ladder: Wolverine is BPC-157 and TB-500, GLOW is that pair plus the copper peptide, KLOW is GLOW plus KPV. KLOW vs GLOW compares what the added KPV changes in composition, FDA status and price per vial.
KPV is a synthetic tripeptide, Lys-Pro-Val, corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone. It does not contain the His-Phe-Arg-Trp "message" sequence that binding at the melanocortin receptors depends on, and its reported activity does not appear to be mediated by those receptors. Cell and rodent work instead describes it entering intestinal and immune cells through PepT1, a proton-coupled oligopeptide transporter, and suppressing activation of NF-kB, which lowers downstream synthesis of pro-inflammatory cytokines.
That places KPV on a different axis from the other three, which are studied in tissue-repair models. GHK-Cu delivers Cu2+ to tissue, where copper is a cofactor for connective-tissue enzymes. BPC-157 is a 15-amino-acid sequence corresponding to a fragment of a protein from human gastric juice, and thymosin beta-4 is a 43-residue actin-sequestering protein.
The four share no sequence, no origin and no mechanism. Selling them as a fixed quartet is a market convention rather than a pharmacological one. No controlled human trial has tested the combination, and each component's own clinical record is on its page (GHK-Cu, BPC-157, thymosin beta-4). KPV and the fragment sold as TB-500 have none.
"TB-500" covers two molecules: full-length thymosin beta-4 and the N-acetylated seven-residue TB-500 Frag 17-23. A KLOW listing that names its component only as "TB-500" does not say which, and the certificate of analysis is the only reliable check. The Wolverine blend page covers that ambiguity in full.
PeptideScouter records a blend's size as the total peptide content of the vial, summed across every component. In KLOW that total is dominated by GHK-Cu, which is 62.5 percent of the mass and by a wide margin the least expensive of the four per milligram. A KLOW vial's price per milligram therefore tracks the copper peptide rather than the three compounds making up the rest of the vial. Adding KPV raises the total load without changing the copper load, so the figure is somewhat less copper-dominated than GLOW's, where the same 50 mg sits in a 70 mg vial.
None of the four components is an FDA-approved drug, and the blend as sold is not a compounded prescription product.
The component that distinguishes KLOW from GLOW is therefore one of the three that were reviewed, while the component making up most of the vial has not yet been before the committee, and the GHK-Cu page tracks its review. Full-length thymosin beta-4 was not the substance at any of these steps, so none of them covered the TB-500 in a vial that holds the full chain. The recommendations are advisory either way: the list changes only through notice-and-comment rulemaking. Our writeup of the July 2026 PCAC vote covers all seven substances heard that week.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
KLOW is a four-peptide combination of GHK-Cu, BPC-157, TB-500 and KPV in a single vial. An 80 mg vial, the total that KLOW-80 names, holds 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, which is the GLOW formula with 10 mg of KPV added. KLOW is a vendor trade name rather than a scientific designation, and material sold by research peptide vendors is offered for laboratory use only, not for human consumption.
They are three points on the same ladder. Wolverine is BPC-157 plus TB-500. GLOW is that pair plus GHK-Cu, the copper tripeptide. KLOW is GLOW plus KPV, an alpha-MSH-derived anti-inflammatory tripeptide, and the K in the name is that addition. The trade names are used consistently enough across vendors to work as a decoder, and where a number is appended, as in GLOW-70 or KLOW-80, it states the combined milligram load rather than a different formula.
A CAS Registry Number identifies a single chemical substance, and KLOW is a mixture of four. The components carry their own: GHK-Cu is 89030-95-5, BPC-157 is 137525-51-0, KPV is 67727-97-3, full-length thymosin beta-4 is 77591-33-4, and the seven-residue TB-500 fragment is 885340-08-9. A certificate of analysis for a blend should report each component separately, which is also the only way to confirm which of the two TB-500 molecules is in the vial.
The comparison takes care, because PeptideScouter records the blend's size as the total peptide content of the vial. GHK-Cu is 62.5 percent of a KLOW vial by mass and costs far less per milligram than BPC-157, TB-500 or KPV, so the blend's per-milligram figure mostly reflects the copper peptide rather than the other three. The like-for-like benchmark is a mass-weighted average of the four component prices. The price table on this page lists the blend's own listings, and each component's live prices are on its own page.
No. Nominations to the Section 503A bulk drug substances list are made per substance, and no combination product was before the Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting. BPC-157 and KPV were, and so was TB-500 in its seven-residue fragment form, and the committee voted to recommend adding all three. Full-length thymosin beta-4 was not on the agenda. GHK-Cu was not among the seven substances heard, so the component that makes up most of the vial has not yet been before the committee. Those votes are advisory, the FDA changes the list only through notice-and-comment rulemaking, and none of it applies to research-grade material sold by peptide vendors.
KLOW Blend is sold by 45 research peptide vendors indexed on PeptideScouter, with 62 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
44 of the 45 indexed vendors currently have KLOW Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Helixion Labs currently lists KLOW Blend at $0.44/mg, the lowest listed price across 45 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.39/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 45 vendors listing KLOW Blend publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $0.44/mg listed to $0.39/mg at Helixion Labs. Each vendor's code is shown beside its price in the table above.
KLOW Blend ranges from $0.44/mg to $3.00/mg across 62 listings from 45 research peptide vendors, normalized to USD per milligram and refreshed daily.
45 research peptide vendors currently list KLOW Blend on PeptideScouter, with 44 in stock right now. We track 62 listings across size and kit variants.
